AbCellera Biologics 2025 Q3 Earnings Revenue Beats Estimates, Net Loss Widens 11.8%

AbCellera Biologics (ABCL) reported fiscal 2025 Q3 earnings on November 6, 2025, with revenue exceeding expectations while net losses deepened. The stock’s post-earnings price action underscored persistent volatility, and CEO Carl Hansen highlighted strategic progress amid ongoing financial challenges.

Revenue

AbCellera Biologics’ total revenue surged 37.6% year-over-year to $8.96 million in Q3 2025, outpacing the FactSet estimate of $6.3 million. This marked a significant improvement from the $6.51 million recorded in the prior-year period.

Earnings/Net Income

The company’s net loss widened to $57.12 million in Q3 2025, a 11.8% increase from the $51.11 million loss in Q3 2024. Earnings per share (EPS) declined to -$0.19 from -$0.17, reflecting higher research and development (R&D) expenses of $55.0 million driven by internal programs. The EPS result missed the Zacks Consensus Estimate of -$0.17 by $0.02.

Post-Earnings Price Action Review

The strategy of buying ABCL shares on the date of its earnings announcement and holding for 30 days showed poor performance over the past three years. While the initial 30-day window captured a 19.2% stock price rise, this was followed by a substantial downturn. Over the entire three-year period, the strategy yielded a -25.1% return, underperforming the simple buy-and-hold approach, which delivered a -14.8% return. This highlights the strategy’s ineffectiveness in ABCL, especially considering the volatility surrounding its earnings announcements.

CEO Commentary

Carl Hansen, Ph.D., CEO of AbCellera, emphasized the company’s execution of two strategic priorities: initiating operations at its new clinical manufacturing facility and completing platform investments. He noted $680 million in available liquidity—comprising $523 million in cash and $159 million in non-dilutive government funding—to advance lead programs through Phase 1 trials and expand the pipeline. The tone balanced progress in clinical development with ongoing net losses and R&D costs.

Guidance

AbCellera reiterated its focus on advancing ABCL635 and ABCL575 through Phase 1 trials but provided no explicit numerical guidance. Forward-looking statements emphasized leveraging $680 million in liquidity for platform investments and clinical development. The company highlighted 103 cumulative partner-initiated programs and 18 molecules in the clinic as long-term revenue drivers.

Additional News

AbCellera Biologics announced the appointment of Dr. Sarah Nunberg as Chief Medical Officer, bringing over 20 years of clinical drug development experience. The company initiated operations at its new clinical manufacturing facility, a critical step in scaling its platform. Additionally, AbCellera submitted Clinical Trial Applications for ABCL635 and ABCL575, with Phase 1 trials underway in Canada. These developments underscore the company’s transition from a platform-focused entity to a clinical-stage biotech.

The stock price of AbCellera Biologics has dropped 3.82% during the latest trading day, plummeted 15.49% during the most recent full trading week, and declined 21.49% month-to-date. This volatility reflects investor uncertainty around the company’s path to profitability despite strategic milestones.